NS System

Project "NS System" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Neurological disorders, ranging from epilepsy, autism, dementias, Alzheimer’s and Parkinson’s diseases affect 1B people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by brain disorders. Many neurological disorders can be prevented and treated using brain monitoring systems that assume a crucial role in the diagnosis of these diseases. Current monitoring technologies include sub-hairline electroencephalography (EEG)-based systems, EEG caps with gel electrodes and imaging techniques such as functional Magnetic Resonance Imaging (fMRI). However, these solutions are not portable presenting uncomfortable and poor measurement accuracy (EEG cap), no real-time extraction of brain parameters and dynamics (sub-hairline EEG systems) and expensive solutions (imaging techniques). Neurosteer has developed NS System, a forehead-wearable real-time and continuous brain monitoring system with a dedicated software component that interprets brain signals producing biomarkers for level of anesthesia, cognitive load, epilepsy and disorders of consciousness. Doctors and caregivers have direct access to the recorded biomarkers through a customized cloud application and they can modify the therapy if needed, based on the recordings. NS system guarantees effective brain monitoring, real-time extraction of brain biomarkers and brain dynamics prediction with an extremely affordable price for the customers. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, Neurosteer will optimize hardware and software components of the NS system to extract also predictive biomarkers of epileptic and sleeping activities. Clinical trials will then be initiated to obtain the CE mark as a medical device.